Scout Investments Inc. grew its holdings in Edwards Lifesciences Corp (NYSE:EW) by 30.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 123,162 shares of the medical research company’s stock after purchasing an additional 28,570 shares during the period. Scout Investments Inc. owned approximately 0.06% of Edwards Lifesciences worth $28,732,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of EW. Quest Capital Management Inc. ADV bought a new stake in Edwards Lifesciences in the 3rd quarter worth approximately $28,000. Usca Ria LLC purchased a new position in shares of Edwards Lifesciences in the third quarter worth $34,000. Venturi Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the third quarter worth $50,000. San Francisco Sentry Investment Group CA raised its holdings in shares of Edwards Lifesciences by 67.7% in the third quarter. San Francisco Sentry Investment Group CA now owns 265 shares of the medical research company’s stock worth $58,000 after buying an additional 107 shares during the last quarter. Finally, Sound Income Strategies LLC raised its holdings in shares of Edwards Lifesciences by 1,500.0% in the fourth quarter. Sound Income Strategies LLC now owns 320 shares of the medical research company’s stock worth $75,000 after buying an additional 300 shares during the last quarter. Institutional investors own 80.73% of the company’s stock.
A number of research firms have issued reports on EW. Deutsche Bank began coverage on shares of Edwards Lifesciences in a report on Friday, January 3rd. They issued a “hold” rating and a $164.00 price target for the company. UBS Group raised their price target on shares of Edwards Lifesciences from $250.00 to $255.00 and gave the stock a “neutral” rating in a report on Friday, December 6th. Cowen reaffirmed a “buy” rating and issued a $275.00 price target on shares of Edwards Lifesciences in a report on Tuesday, December 17th. Jefferies Financial Group raised their price target on shares of Edwards Lifesciences from $255.00 to $285.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Finally, Raymond James raised their price target on shares of Edwards Lifesciences from $255.00 to $263.00 and gave the stock an “outperform” rating in a report on Friday, December 6th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $237.17.
In related news, CEO Michael A. Mussallem sold 22,850 shares of the stock in a transaction on Friday, November 15th. The shares were sold at an average price of $242.38, for a total transaction of $5,538,383.00. Also, VP Catherine M. Szyman sold 2,500 shares of the stock in a transaction on Friday, October 25th. The shares were sold at an average price of $227.19, for a total transaction of $567,975.00. Following the transaction, the vice president now directly owns 19,605 shares in the company, valued at approximately $4,454,059.95. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 168,872 shares of company stock worth $39,664,536. 1.63% of the stock is owned by insiders.
NYSE:EW traded down $1.16 during mid-day trading on Wednesday, reaching $231.85. The company’s stock had a trading volume of 657,167 shares, compared to its average volume of 1,101,083. Edwards Lifesciences Corp has a 1 year low of $148.79 and a 1 year high of $247.64. The stock has a fifty day moving average of $237.62 and a 200-day moving average of $221.22. The firm has a market capitalization of $48.60 billion, a PE ratio of 49.33, a price-to-earnings-growth ratio of 2.56 and a beta of 0.77. The company has a quick ratio of 2.74, a current ratio of 3.53 and a debt-to-equity ratio of 0.17.
Edwards Lifesciences (NYSE:EW) last released its earnings results on Wednesday, October 23rd. The medical research company reported $1.41 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.19. Edwards Lifesciences had a return on equity of 32.28% and a net margin of 18.64%. The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the prior year, the business posted $1.07 earnings per share. The firm’s revenue for the quarter was up 20.7% compared to the same quarter last year. On average, analysts expect that Edwards Lifesciences Corp will post 5.6 earnings per share for the current year.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Want to see what other hedge funds are holding EW? to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with .